Alternative Data for Soleno Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 15 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,230 | Sign up | Sign up | Sign up |
| X Mentions | 50 | Sign up | Sign up | Sign up |
| News Mentions | 5 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 177 | Sign up | Sign up | Sign up |
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $36.74 |
| Target Price | Sign up |
| Volume | 1,277,176 |
| Market Cap | $2.18B |
| Year Range | $36.74 - $88.49 |
| Dividend Yield | 0% |
| PE Ratio | 104.13 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMarch 12 - GlobeNewswire |
|
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNOMarch 11 - GlobeNewswire |
|
Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the SLNO Class ActionMarch 11 - GlobeNewswire |
|
INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD LawMarch 11 - GlobeNewswire |
|
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens BermanMarch 11 - GlobeNewswire |
|
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineMarch 10 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 66M | 1.1M | 65M | 26M | 28M | 0.470 |
| Q2 '25 | 33M | 700,000 | 32M | -4.7M | -2.8M | -0.090 |
| Q1 '25 | 0 | 0 | 0 | -44M | -42M | -0.950 |
| Q4 '24 | 0 | 0 | 0 | -56M | -49M | -1.270 |
| Q3 '24 | 0 | 0 | 0 | -77M | -79M | -1.830 |
Insider Transactions View All
| Hirano Patricia C filed to sell 13,206 shares at $82.8. July 3 '25 |
| Hirano Patricia C filed to sell 17,036 shares at $84.3. June 26 '25 |
| Hirano Patricia C filed to sell 27,036 shares at $70.1. April 2 '25 |
| Hirano Patricia C filed to sell 30,818 shares at $73.6. March 31 '25 |
| Hirano Patricia C filed to sell 55,086 shares at $67.5. March 31 '25 |
Similar companies
Read more about Soleno Therapeutics (SLNO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Soleno Therapeutics
The Market Cap of Soleno Therapeutics is $2.18B.
As of today, Soleno Therapeutics' PE (Price to Earnings) ratio is 104.13.
Currently, the price of one share of Soleno Therapeutics stock is $36.74.
The SLNO stock price chart above provides a comprehensive visual representation of Soleno Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Soleno Therapeutics shares. Our platform offers an up-to-date SLNO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Soleno Therapeutics (SLNO) does not offer dividends to its shareholders. Investors interested in Soleno Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Soleno Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
